The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Incidence and management of peripheral neuropathy in patients with cHL treated with BV + AVD
Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, discusses the findings of a multi-center retrospective study investigating the incidence and management of peripheral neuropathy (PN) in patients with newly diagnosed classical Hodgkin lymphoma (cHL) receiving brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (BV + AVD). Dr Svoboda explains the reasoning for the trial, shares some key findings, and compares the real-world findings to data from the ECHELON-1 clinical trial (NCT01712490). Dr Svoboda then explains how management strategies differed in various centers. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
